Pro Vise Management Group, LLC Biogen Inc. Transaction History

Pro Vise Management Group, LLC

  • $1.14 Billion
  • Q4 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 09, 2023
SELL
$252.44 - $306.72 $141,618 - $172,069
-561 Reduced 37.4%
939 $260,000
Q2 2022

Aug 08, 2022
BUY
$187.54 - $223.02 $91,519 - $108,833
488 Added 48.22%
1,500 $306,000
Q1 2022

Apr 27, 2022
BUY
$193.77 - $244.14 $196,095 - $247,069
1,012 New
1,012 $213,000

Others Institutions Holding BIIB

# of Institutions
1,014
Shares Held
127M
Call Options Held
1.77M
Put Options Held
2.34M
View Full List

About BIOGEN INC.

BIIB Quotes by TradingView
  • Ticker BIIB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 144,000,992
  • Market Cap $17.2B
  • Description
  • Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...
More about BIIB
Track This Portfolio

Track Pro Vise Management Group, LLC Portfolio

Follow Pro Vise Management Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pro Vise Management Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pro Vise Management Group, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email